Although there is evidence for a projected improvement in survival from annual mammography screening in familial breast cancer (from those largely at low risk of BRCA1/2) under 50 years of age [17, 18], this is the first time that a prospectively observed reasonably large series of BRCA2 carriers has been shown to have an apparent survival advantage from annual screening. This evidence concerns the gene BRCA1 and hereditary breast carcinoma.